BiomX

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell BiomX and other ETFs, options, and stocks.

About PHGE

BiomX, Inc. operates as a clinical-stage microbiome company, which engages in the development of both natural and engineered phage cocktails designed to target and destroy harmful bacteria in chronic diseases, such as cystic fibrosis and atopic dermatitis. Its product pipelines include BX004 and BX005, which are treatments for cystic fibrosis and atopic dermatitis respectively. 

CEO
Jonathan Eithan Solomon
CEOJonathan Eithan Solomon
Employees
57
Employees57
Headquarters
Ness Ziona, Tel Aviv
HeadquartersNess Ziona, Tel Aviv
Founded
2015
Founded2015
Employees
57
Employees57

PHGE Key Statistics

Market cap
4.92M
Market cap4.92M
Price-Earnings ratio
-0.11
Price-Earnings ratio-0.11
Dividend yield
Dividend yield
Average volume
157.68K
Average volume157.68K
High today
$5.18
High today$5.18
Low today
$2.75
Low today$2.75
Open price
$3.08
Open price$3.08
Volume
803.50K
Volume803.50K
52 Week high
$22.06
52 Week high$22.06
52 Week low
$2.75
52 Week low$2.75

Stock Snapshot

As of today, BiomX(PHGE) shares are valued at $3.10. The company's market cap stands at 4.92M, with a P/E ratio of -0.11.

As of 2025-12-09, BiomX(PHGE) stock has fluctuated between $2.75 and $5.18. The current price stands at $3.10, placing the stock +12.7% above today's low and -40.2% off the high.

BiomX(PHGE) shares are trading with a volume of 803.5K, against a daily average of 157.68K.

During the past year, BiomX(PHGE) stock moved between $2.75 at its lowest and $22.06 at its peak.

During the past year, BiomX(PHGE) stock moved between $2.75 at its lowest and $22.06 at its peak.

PHGE News

TipRanks 21h
BiomX Discontinues Phase 2b Trial for BX004

TipRanks Cyber Monday Sale Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRank...

TipRanks 22h
BiomX discontinues Phase 2b BX004 trial, plans cost-cutting measures

BiomX (PHGE) announced its discontinuation of the ongoing Phase 2b clinical trial of nebulized phage therapy BX004 in patients with CF associated with chronic P...

People also own

Based on the portfolios of people who own PHGE. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.